New FOAs for U.S.-South Africa Collaborative Research

Established in 2013 as a joint effort between NIH and the South African Medical Research Council (SAMRC), the U.S.-South Africa Program for Collaborative Biomedical Research continues into Phase 2* with four new funding opportunity announcements (FOAs). NIAID is one of five NIH institutes and centers participating in the FOAs.

If your research focus is on HIV/AIDS or HIV/AIDS-associated malignancies, see RFA-AI-19-022 (R01, Clinical Trial Optional) or RFA-AI-19-023 (U01, Clinical Trial Optional).

For proposed research on infectious diseases, including tuberculosis, sexually transmitted infections, parasitic infections, arboviruses and emerging/re-emerging viral pathogens, and vector biology and control, check out RFA-AI-19-024 (R01, Clinical Trial Optional) or RFA-AI-19-025 (U01, Clinical Trial Optional).

*The Phase 1 period was from fiscal years 2015 to 2019.

Common FOA Features

Here, we highlight a few features that apply to all four FOAs. For complete details, including background, research areas of interest, and topics that we will consider nonresponsive, carefully read the announcement in which you are interested; see RFA links above.

  • Applications must include at least one project director/principal investigator (PD/PI) affiliated with a U.S. institution and a South African PD/PI from an eligible institution from South Africa.
  • U.S. and South African investigators will work together to prepare a single application, which must follow the multiple PI approach. The contact PI must be from South Africa and the South African institution submits the application.
  • Applications are encouraged to include scientists associated with historically disadvantaged institutions and underrepresented scientists (from African, Coloured, and Indian population groups) within South Africa.
  • Applications may include scientists from other African countries, particularly Uganda, Kenya, Lesotho, and Zimbabwe, with some limitations noted in the FOAs.  
  • The application deadline is July 26, 2019.

Additionally, applications for the U01 FOAs must include an investigator from an NIH intramural lab who will serve as a project scientist with an equal role in conceptualizing, designing, and executing the research. If your U01 application has an NIH intramural scientist as project scientist, you do not need a separate U.S. PD/PI; listing the intramural scientist as a PD/PI will suffice.

To learn about NIAID’s intramural program and the research interests of its PIs, go to Division of Intramural Research and Investigators’ Research Areas, respectively. NIH’s Intramural Research Program also has helpful information.

Budgets and Project Periods

Opportunity

Research Type

Budget Limits (per year)

Maximum Project Period

RFA-AI-19-022

HIV/AIDS R01

$350,000 in total costs

Five years

RFA-AI-19-023

HIV/AIDS U01

$250,000 in total costs

Five years

RFA-AI-19-024

Non-HIV/AIDS R01

$350,000 in total costs

Five years

RFA-AI-19-025

Non-HIV/AIDS U01

$250,000 in total costs

Five years

You Have Questions, We Have Answers

Check out the following webpages that may address inquiries or concerns you may have.

If you can’t find what you’re looking for in the Questions and Answers or the FOAs, reach out to the scientific/research contacts listed in Section VII. Agency Contacts of the relevant FOA.

Content last reviewed on April 3, 2019

Browse all Articles